← Human Trials & Peer-Reviewed Studies
C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.
Plain-language guide to PMID 8287162 (1993): randomized controlled trial of C-Peptide in 582 patients, diabetic retinopathy and glaucoma.
Key Facts
- PMID
- 8287162
- Journal
- Annals of epidemiology
- Year
- 1993
- Study type
- Randomized Controlled Trial
- Authors
- Prior MJ et al. (5 authors)
- DOI
- 10.1016/1047-2797(93)90004-n
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at C-Peptide in the context of diabetic retinopathy and glaucoma.
C-peptide data were used to develop sets of clinical criteria for the classification of ETDRS patients and to compare and contrast definitions of type of diabetes used in previous studies.
Why It Was Studied
The Early Treatment Diabetic Retinopathy Study (ETDRS), conducted at 22 clinical centers during the period 1980 to 1989, collected baseline data on C-peptide levels after ingestion of Sustacal in 582 patients with diabetes mellitus, prior to enrollment in the trial.
Constellations of clinical characteristics that could serve as proxies for C-peptide level were ascertained.
Who Took Part
The abstract describes 582 patients taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized study.
The patients were allocated by chance, so the C-Peptide group and the comparison group should start out alike.
What Was Measured
The Early Treatment Diabetic Retinopathy Study (ETDRS), conducted at 22 clinical centers during the period 1980 to 1989, collected baseline data on C-peptide levels after ingestion of Sustacal in 582 patients with diabetes mellitus, prior to enrollment in the trial.
Constellations of clinical characteristics that could serve as proxies for C-peptide level were ascertained.
The subject headings attached to it are Aspirin, C-Peptide, Combined Modality Therapy, Diabetes Mellitus, Diabetic Retinopathy, Discriminant Analysis and Light Coagulation.
What This Means in Plain Language
The paper is a randomized study of C-Peptide in 582 patients in people with diabetic retinopathy and glaucoma.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 1993 (Annals of epidemiology), a journal based in United States.
More context: the C-Peptide compound page, Diabetic retinopathy and glaucoma research.
Our Notes on the Compound
C-Peptide: The 31-amino-acid fragment cut from proinsulin when insulin is made; it has been given as an investigational treatment in a few trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.